ALS treatment gets FDA boost

The US FDA has just given Orphan status to the ALS treatment being developed by Israel’s Kadimastem (see here). The designation qualifies the company for various development incentives and less rigorous bureaucracy. Kadimastem expects results of its Israeli clinical trials in mid-2019.,7340,L-3749031,00.html

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *